Press Releases

November 13, 2018
Odevixibat selected as International Nonproprietary Name (INN) for A4250 A4250 granted Fast Track and additional Orphan Drug designations A4250 Phase 3 trial progressing as planned, new natural history data presented at AASLD Management to host conference call and webcast today at 8:30 a.m.
November 8, 2018
BOSTON , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present at the following investor conferences
October 17, 2018
BOSTON , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to lead product candidate
September 24, 2018
BOSTON , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Dr. Patrick Horn , Chief Medical Officer, is scheduled to present at the Cantor Fitzgerald Global
August 8, 2018

BOSTON , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow